URL has been copied successfully!
Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox.
Good morning. STAT is hosting a virtual event tomorrow on the future of biosimilars. Check it out here.
VCs rush to invest in osteoporosis drugs
Developing drugs for brittle bones has long been a difficult endeavor, due to safety concerns and regulatory barriers. But now with new guidance from the FDA, pharma companies are returning to osteoporosis research, and investors are getting interested.
Please follow us:
